Dr. Mark Houston Curriculum Vitae

1. National Board of Medical Examiners – Completed Parts I-III
2. American Board of Internal Medicine (ABIM) – Diplomat/Certification 1975
3. American Society of Hypertension (ASH) Specialist in Clinical Hypertension (FASH) (1999)
4. American Academy of Anti-Aging Medicine ABAARM – (Board Certification 2003)
5. Masters of Science in Human Nutrition, MS, University of Bridgeport, Connecticut (2003)
6. Masters of Science in Metabolic Medicine, MSc University of South Florida, Tampa, (2013)
7. Certification by AMET: American Aesthetic Medical Educators Training (2010)
8. American Board of Cardiology (ABC) Certification in Hypertensive Cardiovascular Disease (DABC) (2017)

1. One of the Top Cardiovascular Physicians in the US by the Consumer’s Research Council of America. November 2018
2. Top 100 physicians in US. American Heath Council September 2017
3. Top 50 Functional and Integrative Medical Doctors in the USA. August 2017
4. USA Today: Most Influential Doctors in the USA: Selected as Top Physician in both Hypertension and Hyperlipidemia. 2008 and 2009
5. America’s Top Physicians 2008, 2009, 2010, 2011, 2012, 2013, 2014 in Hypertension Consumer’s Research Council of America
6. America’s Best Physicians in Cardiovascular Medicine 2018 by the National Consumer Advisory Board
7. William Hillman Award for Excellence in Teaching: Vanderbilt Medical School 1977-78
8. Harold Harper Award: ACAM 2002
9. Denham Harmon MD, PhD Award: ACAM 2010
10. Integrative Medicine Award for Excellence in Teaching July 2010: IFIM
11. Outstanding Contributions in Education and Business Leadership A4M and MMI December 2017
12. Patients Choice Award 2010 Consumer Reports: USA Edition
13. Fellow of the American Society of Hypertension (FASH) May 2011. NYC Annual ASH meeting
14. Fellow of American College of Nutrition (FACN) 2012.
15. Fellow of the American College of Anti-Aging and Regenerative Medicine FAARM 2013
16. Consultant and honorary lectureship for Cardiovascular Academy Clinic in Stockholm Sweden and Functional Medicine Health Care System in Sweden. 2013-2014
17. Consultant and honorary lectureship for REDOX in Taipai, Taiwan, July 2015
18. Honorary lectureship. CV symposium. A4M Dubai. November 2015.

Hypertension Institute
4230 Harding Pike
Suite 400
Nashville, Tennessee 37205

OFFICE PHONE: 615-297-5551
FAX NUMBER: 615-467-0365

EMAIL: mhoustonhisth@yahoo.com
WEBSITE: hypertensioninstitute.com

1. Associate Clinical Professor of Medicine, Vanderbilt University School of Medicine [1990-2012]
2. Clinical Instructor in the Department of Physical Therapy and Health Care Sciences at George Washington University [2014-present]
3. Adjunct Professor in Metabolic Medicine at the University of South Florida Medical School [2010-2018]
4. Director of the Hypertension Institute and Vascular Biology of Nashville [1990-present]. The Hypertension Institute is one of twenty recognized Cardiovascular Centers of Excellence designated by Consortium of Southeastern Hypertension Control (COSEHC)
5. Medical Director, Clinical Research, Hypertension Institute [1995-present]
6. Section Chief, Division of Nutrition, Hypertension Institute [2003-present]
7. Director, CME, Hypertension Institute [2003-present]
8. Director of Life Extension Institute, Saint Thomas Medical Group, Saint Thomas Hospital [1998-present]
9. Chief Medical Officer of Ageless Solutions Clinics, US
10. Staff Physician, Saint Thomas Medical Group, Saint Thomas Hospital [1990-present]
11. Staff Physician, Vascular Institute, Saint Thomas Hospital [1990-present]
12. Faculty Member, Anti-Aging and Functional Medicine Fellowships, (A4M) University of South Florida (USF) [2005-present] and previously at Wayne State Medical School, Detroit, MI.
13. Faculty, Amercian Society of Hypertension, (ASH), Accredited Hypertension Sales Representative Program (AHSRP) [2010-present]
14. Director Advanced Integrative and Metabolic Cardiovascular Certification Module 16: A4M and University of South Florida Faculty [2011-present]
15. Advisory Council for MVP Holdings and Destination Medical Centers [2011]
16. Board of Directors American College for Advancement in Medicine (ACAM) [2012-present]
17. Founding member and director of the International Society of Integrative Metabolic and Functional Cardiovascular Medicine (ISIMFC) founded in 2012
18. Chief Medical Consultant for Primal MD and Ageback, Dubai, UAE [2015-present]
19. Chief Medical Consultant and Director of Scientific Affairs, Bioceuticals Research, Australia [2015-present]
20. Chief Medical Consultant and Scientific Advisory Board for Vibrant America Labs [2015-present]
21. Key opinion leader and faculty for Personalized Lifestyle Medicine Institute (PLMI)
22. Medical Advisory Board for Metagenics [2017-present]

1. Intern in Medicine, University of California Hospitals, San Francisco, California
2. Resident in Medicine, University of California Hospitals, San Francisco, California
3. Hugh J. Morgan, Chief Resident in Medicine, Vanderbilt University School of Medicine
4. Assistant Professor of Medicine, Vanderbilt University School of Medicine
5. Associate Professor of Medicine, Vanderbilt University School of Medicine
6. Co-Director, Medical Intensive Care Unit, Vanderbilt University Hospital
7. Medical Director, Cooperative Care Center, Vanderbilt University Hospital
8. Co-Director, Department of Medicine Resident Report, Vanderbilt University Hospital
9. Member, Division of General Internal Medicine, Vanderbilt University School of Medicine
10. Member, Primary Care Center, Vanderbilt University School of Medicine
11. Attending Physician, Department of Medicine, Vanderbilt University Hospital
12. Medical Attending in Vanderbilt Emergency Room
13. Staff Physician, Parkview Hospital, Nashville, Tennessee
14. Director, Vanderbilt Medical Center Executive Physical Program and Health Promotion Center
15. Chief, Clinical Section, Division of General Internal Medicine, Vanderbilt University School of Medicine
16. Staff Physician, St. Thomas West Hospital, Nashville, Tennessee
17. Director, Hypertension Institute and Vascular Biology, St. Thomas West Hospital
18. Director, Life Extension Institute, St. Thomas West Hospital
19. Staff Physician, Vascular Institute, St. Thomas West Hospital
20. Associate Clinical Professor of Medicine, Vanderbilt University School of Medicine
21. Adjunct faculty, USF, Tampa. Metabolic Medicine and FAARM

• Fellow, American College of Physicians (FACP)
• Fellow, National Council on High Blood Pressure Research)
• Fellow, International Society for Hypertension in Blacks (FISHIB)
• Fellow, American Heart Association (FAHA)
• Fellow, Council on Nutrition, Physical Activity and Metabolism (AHA)
• Fellow, American Society of Hypertension (FASH)
• Fellow American College of Nutrition (FACN)
• Fellow A4M FAARM

• Jackson High School, Jackson, Tennessee
  1. Valedictorian
• Southwestern at Memphis (Rhodes College)
  1. Graduated Summa Cum Laude
  2. Phi Beta Kappa
  3. Who‘s Who in American Colleges and Universities
  4. Nominated to finals for Tennessee Selection Rhodes Scholar
  5. President of Honor Council
  6. Junior Honor’s Program – Independent Research in Chemistry on Aging, under Dr. Harold Lyons
  7. Omicron Delta Kappa
• Vanderbilt University Medical School and Medical Center
  1. Alpha Omega Alpha
  2. J. William Hillman Award for Excellent in Teaching – Selected as best teacher by 3rd and 4th year medical students : Vanderbilt University Hospital
  3. Henry J. Kaiser Family Foundation Faculty Fellowship Semifinalist
  4. Fellow of the American College of Physicians (FACP)
• St. Thomas West Hospital
  1. The 2002 Harold Harper Lecture Award Role of Vascular Biology, Nutrition and Nutraceuticals in Prevention and Treatment of Hypertension American College for Advancement in Medicine
  2. (ACAM) Fall Conference, November 9 Phoenix, Arizona (2002) Jackson Purchase Cardiovascular Society Distinguished Lecturer Management of Resistant Hypertension 2004 Winter Vascular Symposium January 17 Paducah, Kentucky (2004)
  3. Stroke and Heart Attack Prevention Centers: Medical Director for Hypertension (2006)
  4. Denham Harmon MD, PhD Award by the American College for Advancement in Medicine (ACAM) San Diego, Ca Annual Meeting April 24, 2010
  5. Integrative Medicine Award for Excellence in Teaching and Clinical Medicine: IFIM Las Vegas, NV, July 2010
• University of Bridgeport, Connecticut
  1. Honor Society of Phi Kappa Phi (2003)
• America’s Top Physicians in Hypertension 2008, 2009, 2010, 2011 by the Consumers Research Council of America
• USA Today Most Influential Doctors in USA in both Hypertension and Hyperlipidemia: in 2009 and in two consecutive votes in May and November, 2009
• America’s Top Physicians in Cardiology 2018 by the Consumers Research Council of America
• One of top two physicians in the state of Tennessee in Anti-Aging Medicine in two books: Breakthrough and Knockout by Suzanne Sommers
• Patient’s Choice Award in 2010 in USA Consumer Reports
• Founding member and director of the International Society of Integrative Metabolic and Functional Cardiovascular Medicine (ISIMFC) founded in 2012

1. Sectional Editor (Hypertension, Coronary Heart Disease, Congenital Heart Defect, Congestive Heart Failure, Preventive Cardiovascular Medicine) for Journal of Cardiology and Cardiovascular Sciences. (2017-present)
2. Guest Editor for Nutritional Treatment of Hypertension and Editorial Board for Nutrients (2017-present)
3. Therapeutic Advances in Cardiovascular Disease (Editorial Board) (2012-present)
4. Medical Editor for The Board Examination Review & Study Guide, 2009 Edition of the American Academy of Anti-Aging Medicine (A4M) (2009-present)
5. Editor-in-Chief for Journal of the American Nutraceutical Association (JANA) (2001-2013)
6. Protocols: Strategies from Experts in Cardiology (1990-present) (Editorial Board and Consultant)
7. Austin Hypertension Editorial Board (2016-present)
8. Journal of Restorative Medicine Editorial Board (2015-2017)
9. Annals of Nutritional Disorders and Therapy Editorial Board (2014-present)
10. Metabolic Syndrome and Drug Therapy Editorial Board (2014-2017)
11. Journal of Food and Nutrition Editorial Board (2015-present)
12. Journal of Food and Nutritional Disorders Editorial Board (2014-present)
13. Editorial Board for Protocols: Strategies from Experts in Cardiology (1990-2015)
14. The Journal of the American Nutraceutical Association Editorial Board (2000-2014)
15. Archives of Internal Medicine (Reviewer)
16. American Medical Reports Emergency Medicine Section (Reviewer)
17. American Heart Journal (Reviewer)
18. Southern Medical Journal (Reviewer)
19. Medical Letter (Reviewer)
20. American Journal of Medicine (Reviewer)
21. Hypertension (Reviewer)
22. Annals of Internal Medicine (Reviewer)
23. New England Journal of Medicine (Reviewer)
24. American Journal of Hypertension, Ltd. (Reviewer)
25. Human Hypertension (Reviewer)
26. Journal of the American Medical Association (JAMA) (Reviewer)
27. American Journal of Hypertension (Reviewer)
28. Journal of Clinical Hypertension (Reviewer)
29. Chest (Reviewer)

1. Health Trac Hypertension Advisory Board (1990-present); Stanford, California “Heart and Circulation” Journal (1990)
2. Protocols: Strategies from Experts in Cardiology (Editorial Advisory Board) (1990-2000)
3. National Bureau for Information on Coronary Heart Disease Risk; Connecticut
4. Doxazosin Investigators and Consultants Educational Exchanger; New York, New York
5. Vascular Biology and Hypertension Consultants RDR; Boston, Massachusetts
6. The Consortium for Southeastern Hypertension Control (COSEHC) (External Medical Advisory Board) (2001-2012) and Board of Directors (2002-2012)
7. Chair, American Nutraceutical Association (ANA) (Advisory Council)
8. Member, American Heart Association Council on Arteriosclerosis, Thrombosis, and Vascular Biology
9. Board of Trust and Executive Board Consortium of Southeastern Hypertension Control (COSEHC)
10. Vascular Biology and Hypertension Consultants (RDR)
11. Doxazosin Investigators and Consultant Exchange (DICE)
12. National Bureau for Information on CHD
13. Helios Health Hypertension Expert
14. Kronos Clinical Age Management
15. Vascular Biology Working Group
16. Chair, Medical Advisory Board American Nutraceutical Association (ANA)
17. Vascular Institute St. Thomas West Hospital
18. American Society of Hypertension Committee on Membership (ASH) (2002-2012)
19. The Consortium for Southeastern Hypertension Control CME Committee (COSEHC) (2002-2014)
20. Medical Liaison to Institute of Medicine (IOM) for the National Institutes of Health and Agency for Healthcare Research and Quality for Complementary and Alternative Medicine (ANA Representative), 2003
21. Chair, COSEHC Annual Cardiovascular Symposium (2002)
22. Co-Chair, COSEHC Cardiovascular and Hypertension Guidelines (2004)
23. Global Cardiovascular Risk Registry Steering Committee, COSEHC (2006)
24. Medical Advisory Board for Optimal Health, San Diego, CA (2010)
25. Medical Advisory Board for Rancho Mirage , CA, ICI. (2010)
26. Board of Directors for Jennifer O’Neill Ministries (2010)
27. Medical Advisory Board for Health Intelligence: Solal Technologies (2010)
28. South Africa Scientific Advisory Board for Optimal Health and Prevention Research Foundation, San Diego, CA (2010)
29. Medical Advisory Board for MVP Holdings and Destination Medical Centres.
    Chief Medical Officer for Destination Medical Centres and MVP Holdings
30. American Society of Hypertension ASH Steering Committee for Clinical Hypertension Review Course (2011)
31. Director of the Advanced Integrative Metabolic and Functional Cardiovascular Course for FAARM and A4M with the University of South Florida Medical School.

(Past and Present)

1. Elected Member of the Executive Council, American Society of Hypertension (ASH)
2. Fellow, American Heart Association (FAHA)
3. Consortium of Southeastern Hypertension Control (COSEHC) (2000-present)
4. American Society of Hypertension (ASH) Specialist in Clinical Hypertension (1999)
5. Fellow – National Council on High Blood Pressure (1996-present)
6. American Heart Association National Chapter (AHA)
7. Member of AHA Council on Atherosclerosis, Thrombosis and Vascular Biology
8. American Heart Association Middle Tennessee Chapter (AHA)
9. American Thoracic Society Member (ATS)
10. Nashville Academy of Medicine (NAM) and Davidson County Medical Society (DCMS)
11. Tennessee Medical Association (TMA)
12. Society for Research and Education in Primary Care Internal Medicine (SREPCIM)
13. American Society of Internal Medicine (ASIM)
14. Tennessee Society of Internal Medicine (TSIM)
15. Fellow, American College of Physician (FACP) (Elected 1984)
16. American Medical Association (AMA)
17. Nashville Society of Internal Medicine (NSIM)
18. Society of Critical Care Medicine (SCCM)
19. Southern Medical Society (SMS)
20. American Federation of Clinical Research (AFCR)
21. Secretary, Tennessee Chapter, American College of Physicians (1987-1990)
22. American Society of Hypertension (ASH)
23. The International Society of Hypertension (ISH)
24. The Intra-American Society of Hypertension (IASH)
25. Alternate Delegate to TMA House of Delegates 1994 of Nashville Academy of Medicine (NAM)
26. Delegate to TMA of NAM, 1995, 1996 and 1997
27. Government Affairs Committee, Nashville Academy of Medicine
28. Member of the AHA Council on Arteriosclerosis, Thrombosis and Vascular Biology
29. International Society of Hypertension in Blacks (ISHIB)
30. Southeastern Lipid Association (SELA)
31. Vascular Biology Working Group (VBWG)

• California (Past)
• Tennessee (Present)

(Past)

1. Internship Selection Committee
2. Deputy Chairman, Pharmacy and Therapeutics Committee
3. Chairman, Utilization Review Committee
4. Medical Intensive Care Committee
5. Vanderbilt University Medical Records Committee
6. Chairman and Coordinator Vanderbilt University Ambulatory Care
7. Administration Committee (General Medicine)
8. Chairman, Medical Records Committee
9. Vanderbilt Ambulatory Services Committee
10. ICD-9 Coding Committee

(Past)

1. Vanderbilt Medical School Student Admission Committee Interviewer
2. Medical Housestaff Evaluation Committee
3. Vanderbilt Medical Student Special Programs Committee
4. Promotions Committee for Vanderbilt Medical Students (Years 1-4)
5. Faculty Advisor to VMS Students (Years 1-4)
6. Continuing Education Committee
7. Vanderbilt Medical School Faculty Planning Retreat – Academic Affairs and Educational Programs Conference
8. Co-Director, Continuing Medical Education Committee
9. Chairman, Faculty-Staff Philanthropic Campaign, Vanderbilt Medical Center
10. Member, Ad Hoc Committee on Education and Philanthropy, Vanderbilt University Medical Center
11. Member, Executive Committee, Vanderbilt Professional Practice Program (VPPP)
12. Vice-Chairman, ICD-9 Coding Committee

(Present)

1. National Heart Attack Risk Study Advisory Committee
2. Continuing Medical Education Committee
3. Institutional Review Board
4. Education and Research Strategic Planning Work Group
5. Utilization Review Committee
6. Vascular Institute Committee and Review Board

(Past)

1. Co-Director, Medical Intensive Care Unit, VUH including:
   1. Informal morning rounds
   2. Attending Physician in Medical ICU
   3. Core Curriculum Course for Medical ICU
2. Attending Physician Preceptor Medical Ward Teams, VUH (Blue Teams)
   (2 months/year)
3. Attending Physician Preceptor for 3rd and 4th year medical students rotating on medicine at VUH
   (2 months/year)
4. Attending Physician Preceptor and Tutor for 4th year medical students I Medicine Clerkship in General Medicine elective Vanderbilt Medical Clinic (daily)
5. Attending Faculty Preceptor, Medical Consult Service, VUH (2 months/year)
6. Instructor for informal lectures with Vanderbilt housestaff and medical students
7. Morning Ward Rounds informal bedside teaching with medical housestaff and students (daily)
8. Instructor in Clinical Practice Management Course
9. Instructor in Critical Care and Emergency Medicine Series )
10. Preceptor: Internal Medicine Residents General Medicine Clinic (Weekly, Monday a.m. 4 hours)
11. General Internal Medicine Core Curriculum, VMS 4, 1-2 hours/month
12. Attending, Medical Consult Service, 2 months/year)

(Past)

1. Attending Physician Green Teaching Service (1-2 months/year) VMS 3, VMS 4 and Vanderbilt Housestaff
2. Physical Diagnosis Tutor (4 months/year) for VMS 2 (have participated as Physical Diagnosis Tutor for 2nd year medical students consecutively)
3. Faculty Advisor to Vanderbilt Medical Students
4. Lecturer POD Service Attending Red Resident Critical Care Medicine. Lecture Series (Fridays)
5. Tutorial Outpatient Medicine 3rd and 4th year Vanderbilt Medical Students
6. Medical Monthly Education Program (MMEP) United Negro College Fund Fisk University Vanderbilt Premedical Summer Institute: Faculty Preceptor
7. Primary Care Medicine (PCM) Clerkship, Faculty Preceptor

1. Medical Director for the Wellness Channel of REZOOM Internet Site 2007
2. Chief Medical Editor for PRESENT CARDIOVASCULAR INTERNET CME TRAINING for physicians worldwide 2008
3. SHARECARE: 2011

1. Evaluation of Antihypertensive Therapy. (Clonidine vs Propranolol) On Glucose Tolerance in the Hypertensive Patient with Diabetes Mellitus. Vanderbilt University Medical Center (1980-1983). (Completed). (B.I.L. Grant) Published in part in Cardiology Clinics 14:117-135, February, 1986.
2. Evaluation of Atrovent in Chronic Obstructive Pulmonary Disease. Vanderbilt University Medical Center (1980-1983) (Completed). (B.I.L. Grant).
3. Evaluation of CL 115, 347 (Prostaglandin E). An Oral and Transdermal Prostaglandin Antihypertensive as Monotherapy in Combination with Hydrochlorothiazide in Mild to Moderate Hypertensive Patients, Vanderbilt University Medical Center (1984). (Completed). (Lederle Grant). (No publication. Drug withdrawn from clinical trails). Co-investigators: Dr. John Nadeau and Dr. Alastair Wood in Clinical Pharmacology SCOR.
4. Evaluation of Antihypertensive Therapy (Clonidine and Atenolol) on Serum Lipids, Apoproteins and HDL Subfractions and Glucose in Mild Essential Hypertension. Vanderbilt University Medical Center (1984-1990), (Completed). (B.I.L. Grant). Co-investigators: Dr. John Nadeau, Dr. Taylor Hays, Dr. Larry Swift, Dr. Charles Bradley, Clinical Pharmacology, SCOR and Department of Pathology. (Abstract Published in American Federation of Clinical Research, January, 1987.) Manuscript published inAmerican Heart Journal, 1990; 120:172-179.
5. Evaluation of Clonidine and Yohimbine on Plasma Volume, Sodium Excretion and Clinical Symptoms in Mitral Valve Prolapse Autonomic Dysfunction and Normals. Vanderbilt University Medical Center. (Completed). (No publication anticipated). Co-investigators: Dr. David Robertson and Dr. Jack Onrot, Clinical Pharmacology.
6. Retrospective Analysis of Medical Consult Service. Vanderbilt Hospital (1982-1984). (Completed). Published in Southern Medical Journal 80:176-180, December 1987. Co-investigators: Dr. Taylor Hays, Dr. Frank Gluck and Dr. David Ratcliff.
7. Evaluation of Regression of Left Ventricular Hypertrophy in Mild to Moderate Hypertension with Various Antihypertensive Agents. Clinical Study with the Division of General Internal Medicine, Division of Cardiology, SCOR in Hypertension and Critical Care Unit, Vanderbilt Medical Center. (Completed). (American Heart Association Grant). Co-investigators: Dr. Marvin Kronenberg, Dr. John Nadeau and Dr. Ben Byrd, Clinical Pharmacology, SCOR and Cardiology.
8. Comparison of Mild, Moderate and Severe Hypertensive Patients in Cooperative Care Center Versus University Hospital Patients: Effects of an Education Program on Patient Compliance and Blood Pressure Control. (Completed). Co-investigators: Beth Pulliam, R.N. and Kathy Gibson, R.N. (Abstract published: National Council on High Blood Pressure, 1989).
9. The Effects of Topical Minoxidil in Untreated Mild Hypertensive Patient. Vanderbilt University Medical Center. (Completed). (Upjohn Grant). (Multicenter study to be published). Co-investigator: Dr. John Nadeau, Clinical Pharmacology and SCOR.
10. Pharmacokinetics of Bepridil in Patient with Ischemic Heart Disease: Comparison of Single Versus Multiple Dose Kinetics. (Completed). (Drug withdrawn from clinical trials). (No publication anticipated). Co-investigator: Dr. Ray Woosley.
11. Effect of Guanabenz on Natriuretic Hormone and Atrial Natriuretic Factor in Patients with Essential Hypertension. (Completed). (Wyeth Grant).
12. Comparative Effects of Nifedipine, Atenolol and Placebo on Serum Lipids, Lipoproteins, Lipid Subfractions and Glucose in Mild Hypertensive Patients. (Pfizer Grant). Co-investigator: Dr. Mike Lichtenstein. (Abstract published in ASH Meetings, AFCR and International College of Angiology 1990). Completed May 1992.
13. Clinical Evaluation of Clonidine, Hydrochloride and Catapres-TTS in Smoking Cessation (1987). (B.I.L. Grant). (Completed). Co-investigators: Dr. Craig Heim and Dr. Mike Lichtenstein, Division of General Internal Medicine.
14. Effect on Glucose Tolerance with Hydrochlorothiazide or Angiotensin Converting Enzyme Inhibitor Monotherapy Captopril and Mechanism of Antidiabetic Effect in Hypertensive Patients with Diabetes Mellitus (1986). Co-investigator: Dr. Taylor Hays. (Squibb Grant). (Completed).
15. Open Evaluation of the Efficacy and Safety of Wytensin (Guanabenz) Administered Orally in the Treatment of Hypertensive Type II Diabetic Outpatients. (Wyeth Pharmaceuticals Grant). (Completed).
16. An Evaluation of Efficacy of Wytensin (Guanabenz) when Added to Non-Excellent Responders to Dyazide with Mild to Moderate Hypertension. (Wyeth Pharmaceuticals Grant). (Completed).
17. Comparative Effects of Captopril, Thiazide Diuretics, and Placebo on Serum Lipids, Lipoproteins, Lipid Subfractions, Glucose, Potassium and Quality of Life in Mild to Moderate Hypertensive Patients. (Squibb Grant). (Completed).
18. Comparative Study of Clarithromycin and Penicillin VK in the Treatment of Patients with Streptococcal Pharyngitis. (Abbott Labs Grant). Co-investigator: Dr. Mark Jacokes. (Completed).
19. Effect of Catapres-TTS in Alcohol Withdrawal and Chronic Abstinence. (B.I.L. Grant 1988). Principal Investigator: Dr. Peter Martin. Co-investigators: Dr. Mark Houston and Dr. Anderson Spickard. (Completed).
20. Dose Response Evaluation of Diltiazem.in Patients with Hypertensive Urgency. (Marion Labs Grant). (Completed 1990).
21. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Clinical Study to Determine the Dose-Response Relationship to Diltiazern Extended Release (ER) in Patients with Mild to Moderate Hypertension. Merck, Sharp and Dohme Research Laboratories 1989.
22. Catapres-TTS and Procardia XL in the Treatment of Mild Hypertension. (B.I.L. Grant, 1990). (Completed).
23. Quinapril Monotherapy Clinical Trial in Mild to Moderate Hypertension.
24. Double-Blind, Placebo-Controlled, Dose Titration Study of the Safety and Efficacy of Dilacor XR in Elderly Patients with Mild to Moderate Hypertension. Rhone-Boulenc Rorer Grant 1992.
25. Insomnia Treatment Study Comparing Triazolam and Temazepam. Upjohn Grant 1992.
26. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Nonsteroidal Anti-Inflammatory Drugs (NSAID’s) on Blood Pressure in Patients with Mild to Moderate Hypertension Controlled by Verelan. Wyeth Ayerst Grant 1992.
27. HOT Study. Hypertension Optimal Treatment International Study. Astra Merck. (Completed).
28. A Multicenter, Prospective, Randomized, Controlled, Double-Blind Study Examining the Effects of Substituting Norvasc for Procardia XL in the Treatment of Essential Hypertension. Pfizer. (Completed).
29. ALLHAT Study (NHLIB). Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial. University of Texas. (Completed 2003).
30. Double-Blind, Randomized, Multicenter Trial Comparing Once-Daily Verelan Versus Norvasc in Women with Mild to Moderate Essential Hypertension. Lederle Laboratories, Wyeth Ayerst Laboratories. (Completed 1997).
31. A Triple-Blind Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients with Left Ventricular Hypertrophy. Merck & Company, Inc. (Completed 1998).
32. RESOLVD. Randomized Evaluation of Strategies for Left Ventricular Dysfunction. Pilot Study. A Two Staged Randomized Trial of Candesartan, Enalapril, and Metoprolol in Patients with Congestive Heart Failure. Canadian Cardiovascular Council. (Completed 1998).
33. TARKA. Trandolapril in Hypertension: Effectiveness When Added to Verapamil SR. Knoll Pharmaceutical Company. (Completed 1998).
34. A-TIME Study. Accupril Titration Interval Management Evaluation. Parke-Davis. (Completed 1997).
35. A Comparison of the Safety and the Efficacy of Mibefradil and Amiodipine in Hypertensive, Non-Diabetic Patients and Hypertensive, Non-Insulin Dependent Diabetic Patients. Roche Pharmaceuticals. (Completed 1998).
36. A 54-Week Open Label Assessment of the Safety and Efficacy Profile of Atorvastatin as Compared to Simvastatin when Used to Optimally Control Patients with Mixed Dyslipidemia. Parke-Davis. (Completed 1996).
37. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Measuring the Effects of Cl-991 on Non-insulin Dependent Diabetes Mellitus (NIDDM) Patients Requiring Insulin. Parke-Davis. (Completed 1997).
38. A Randomized, Double-Blind, Parallel Trial Comparing Lotrel 5/10 mg. Once Daily, Lotrel 5/20 mg. Once Daily, Nifedipine GITS 30 mg. Once Daily, and Nifedipine GITS 60 mg. Once Daily in Patients Age 18-80 Years with Essential Hypertension Inadequately Controlled with Nifedipine ITS 30 mg. Once Daily Followed by a Single-Blind Extension of Lotrel 5/20 mg. Once Daily. CIBA. (Completed 1997).
39. CONVINCE. Clinical Protocol for Controlled Onset Verapamil Investigation of Cardiovascular Endpoints. Searle & Company. (Completed 2002).
40. TROPHY. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Long-Term Trial of Preventing Hypertension Using Candesartan Cilexetil 16 mg in Patients with High Normal Blood Pressure. Astra Pharmaceuticals, L.P. (Completed August 2005).
41. INVEST. International Verapamil-SR Trandolapril Study. Knoll. (Completed January 2003).
42. A Randomized, Double-Blind, Active-Controlled Study of the Antihypertensive Response to Omapatrilat in Subjects Uncontrolled on ACE-Inhibitor Therapy. Bristol-Myers Squibb. (Completed May 2001).
43. BELLES. Beyond Endorsed Lipid Lowering with EBT Scanning. Pfizer. (Completed 2001).
44. Evaluation of Coronary Heart Disease Regression by EBT in Patients Treated with Concentrated Fruit and Vegetable Extracts. National Safety Associates. (Completed 2004).
45. OCTAVE. Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril. Bristol-Myers Squibb. (Completed July 2001).
46. AVALON. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled and Open-Label Evaluation of the Safety and Efficacy of Dual Therapy with Atorvastatin Plus Amlodipine when Compared to Either Therapy Alone in the Treatment of Patients with Simultaneous Hyperlipidemia and Hypertension. Pfizer. (Completed January 2003).
47. STARS. A Multi-Center, Open-Label, 12-Week Study to Evaluate the Glycemic Control Achieved in StarLix 120 mg in Subjects with Type 2 Diabetes Mellitus in a Practice-Based Setting. Novartis. (Closed).
48. PRESERVE. A Multi-Center, Randomized, Double-Blind, Active Controlled Trial to Compare the Efficacy and Safety of 104 Weeks of StarLix (Nateglinide) Plus Metformin vs. Glyburide Plus Metformin in Drug Naïve Subjects with Type 2 Diabetes Mellitus who have Inadequate Glycemic Control with Diet and Exercise. Novartis. (Completed April 2004).
49. Hypertension Formula Study. A 40 Subject, Placebo-Controlled Trial to Compare the Efficacy of Vasatrol vs. Placebo. (Completed 2002).
50. Hypertension Natural Treatment Vasatrol II Study. A 12 Subject Trial. (Completed December 2002).
51. CCOX 189A2332. An International, Multi-Center, Stratified, Randomized, Double-Blind, Double-Dummy, Parallel-Group, 52-Week Gastrointestinal Clinical Safety Study to Demonstrate that COX 189 (400 mg od) Reduces the Risk to Develop Complicated Ulcers as Compared to NSAID’s (Naproxen 500 mg bid and Ibuprofen 800 mg tid) in Osteoarthritis Patients. Novartis. (Completed March 2004).
52. A Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients with Mild to Moderate Hypertension. Bertek Pharmaceuticals, Inc. (Completed August 2003).
53. EASE. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg/day when Added to Ongoing Therapy with a Statin Versus Statin Therapy Alone in Patients with Hypercholesterolemia who have not Reached National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III LDL-Cholesterol Level. Merck & Co., Inc. (Completed November 2003).
54. ADHERE. A Multi-Center, Randomized, Double-Blind, Double-Dummy Study Evaluating the Safety and Efficacy of the Addition of Amlodipine to Quinapril or Losartan in the Treatment of Diabetic Hypertensive Subjects. Pfizer Pharmaceuticals Inc. (Closed November 2003).
55. Aliskiren. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparing Aliskiren 150 mg, 300 mg, and 600 mg to Placebo and Irbesartan 150 mg in Patients with Mild to Moderate Essential Hypertension. Novartis Pharmaceuticals Corp. (Completed December 2003).
56. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Forced Titration, Comparison of Micardis HCTZ (Telmisartan 80 mg/HCTZ 25 mg) Versus Diovan HCTZ (Valsartan 160 mg/HCTZ 25 mg) Using Seated Trough Cuff Blood Pressure in Patients with Stage 1 and Stage 2 Hypertension. Boehringer Ingelheim Pharmaceuticals. (Completed April 2004).
57. A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan (320 mg) and HCTZ (12.5 and 25 mg) Combined and Alone, Valsartan 160 mg and Valsartan 160 mg/HCTZ 12.5 mg in Hypertensive Patients. Novartis. (Completed May 2005).
58. ACCOMPLISH. A Prospective, Multi-National, Multi-Center, Double-Blind, Randomized, Active-Controlled Trial to Compare the Effects of Lotrel to Benazapril and HCTZ Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients with High Risk Hypertension. Novartis. (Completed)
59. A Multi-Center, Randomized, Double-Blind Study to Compare the Effects of 24-Weeks Treatment with LAF237 (50 mg QD, 50 mg BID or 100 mg QD) to Placebo in Drug Naïve Patients with Type 2 Diabetes. Novartis. (Completed July 2006)
60. A Multi-Center, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24-Weeks Treatment with LAF237 (50 mg QD or BID) to Placebo as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy. Novartis. (Completed May 2006)
61. A Multi-Center, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24-Weeks Treatment with LAF237 (50 mg QD or BID) to Placebo as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Thiazolidinedione Monotherapy. Novartis. (Completed August 2006)
62. Oral Ribose in the Treatment of Statin-Induced Myalgias 30 Patient Study. Bioenergy, Inc. (Completed November 2004)
63. Oral Ribose in the Treatment of Statin-Induced Myalgias 50 Patient Study. Bioenergy, Inc. (Completed December 2005)
64. Evaluation of a Tocotrienol Complex on Serum Lipids in Human Subjects. Designs for Health. (Completed May 2006)
65. A Double-Blind, Randomized, Placebo-Controlled Factorial Study to Evaluate the Efficacy and Safety of TAK-475 and Simvastatin Alone and in Combination in Subjects with Hypercholesterolemia. Takeda. (Completed April 2007)
66. A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 or Placebo When Co-Administered with Fenofibrate in Subjects with Combined Hyperlipidemia. Takeda. (Completed March 2007)
67. Plasma Renin Activity as a Physiologic Marker for the Selection of Appropriate Anti-Hypertensive Drug Therapy in Patients Unsuccessfully Treated on Multiple Drugs: The Laragh Method. Cardiovascular Center at the New York Presbyterian Hospital Cornell Medical Center and Weill Medical Center. (Closed October 2006)
68. AGELESS. A 36-Week, Randomized, Double-Blind, Parallel Group, Multi-Center, Active-Controlled, Optimal Titration Study Comparing an Aliskiren-Based Regimen to a Lisinopril-Based Regimen in Patients > 65 Years Old with Systolic Essential Hypertension. Novartis. (Completed)
69. LIPIDSIRT Study: 2 month evaluation of 40 patients with dyslipidemia. Biotics . Completed 2012
70. Insomnia Study: One month evalution of 40 patients with chronic insomnia with a nutritional supplement Completed 2012
71. Hypertension Study: Evaluation of CardioSirt BP in Hypertension patients: Biotics Research Completed and published 2012
72. Acute response to NEO 40 in hypertensive patients :Evaluation of BP and ENDOPAT Neogensis Published JCH 2014
73. Evaluation of Pea Protein Powder on BP in Hypertensive patients: DFH 2013
74. Evaluation of Protandim on Endothelial function in normal subjects 2014
75. Poetry study of the Elderly for CYP 450 Drug metabolism and interactions 2014
76. Lipocardia study for treatment of dyslipidemia Thorne Research 2014-2015
77. Cardiopressin Clinical Trial on Hypertension Thorne Research 2015-17
78. RADAR PGX genotype study for CYP Drug Metabolism and Interactions 2016-17
79. Evaluation of NEO 40 in patients with elevated ADMA and SDMA and effects on endothelial dysfunction, augmentation index, HRV, inflammation and oxidative stress parameters. 2017 Neogenis Research Corp.
80. Clinical Evaluation of TA65 on Cardiovascular function, inflammation and immune function: August 2018 start. Ongoing.
81. The Role of the Fasting Mimicking Diet on Cardiovascular Risk Factors, Cardiovascular Function and Structural Parameters. Start Jan 2019. Ongoing
82. The Efficacy and Adverse Effects of Arterosil on Hypertension Subjects: Ongoing

1. Section Director, Medical Intensive Care Course, TSIM and Tennessee Region ACP.
2. Program Director of Symposium on “The Treatment of the Complicated Patient with Hypertension”. University of Tennessee and Vanderbilt Medical Center.
3. Director, Core Curriculum Course, Medical Intensive Care Unit. Vanderbilt Hospital.
4. Program Director, Symposium, on Hypertension, Shock and Respiratory Disease. Family Practice Center. University of Tennessee. Jackson, Tennessee.
5. Invited Panelist for International Symposium on Hypertension held in Geneva, Switzerland
6. Director of the American College of Physicians Scientific Program for Associates. Vanderbilt Hospital. Nashville, Tennessee.
7. Guest Expert American College of Physicians Annual Session State of Tennessee Fall Retreat.
8. Invited Panelist on “The Cardiovascular System in the Elderly”. International Symposium held in Montreaux, Switzerland.
9. Invited Lecturer Australia National Symposium, , held in Sidney, Melbourne, Adelaide, Brisbane, and Perth.
10. International Symposium on Nifedipine GITS and Hypertension Therapy. Cannes, France.
11. International Symposium on Clonidine TTS and Hypertension. Indonesia.
12. International Society of Hypertension (ISH) Satellite Symposium on Nifedipine GITS. Madrid, Spain.
13. Modern Concepts in Hypertensive Therapy, Co-Chairman. Tampa, Florida.
14. International Lecture Tour. Oslo, Norway and Medical Universities in Norway.
15. Hypertension Institute, St. Thomas West Hospital Annual Hypertension and CV Symposium.
16. Hypertension Optimal Therapy (HOT) Study Clinical Investigator Meeting. Brussels, Belgium.
17. Ultimate Healing: Prayer, Faith, Religion and Medicine: 8 Hour Symposium. Lake Junaluska, North Carolina.
18. Ultimate Healing: Prayer, Faith, Medicine and Religion. Director and Speaker. Vanderbilt University Medical Center.
19. Role of Prayer, Faith, Medicine and Healing. Lake Junaluska, North Carolina
20. Course Director, Public Health Life Extension Lecture Series. St. Thomas West Hospital.
21. Chair, Annual Scientific Session of COSEHC (Consortium of Southeastern Hypertension Control). Savannah, Georgia and Nashville, Tn.
22. Director A4M Module 2 Cardiovascular Medicine
23. Director IFIM Integrative Cardiovascular Medicine Modules
24. Director A4M Advanced Cardiovascular Medicine Certification and Modules
25. Cardiovascular Medicine Module 5: IFM- Institute for Functional Medicine
26. Stockholm ,Sweden CV Functional Medicine Symposium with Health Care Ministry and Allied Health Professionals
27. Invited lecture and Keynote Australian Symposium Sydnye

1. Growdon W, Bratton T, Houston MC. Brain Glucose Metabolism in the Intact Mouse. American Journal of Physiology 221:1738-1745, 1971.
2. Porter LL, Houston MC, Kadir S. Mycotic Aneurysms of the Hepatic Artery: Treatment with Arterial Embolization. American Journal of Medicine 67:697-701, 1979.
3. Houston MC. Clonidine Withdrawal – Fact or Fiction? Western Journal of Medicine 131:449-450, 1979.
4. Houston MC. The Diagnosis and Treatment of Shock. Southern Medical Journal 73:477-484, 1980.
5. Houston MC. Clonidine Hydrochloride. Annals of Internal Medicine 92:718, 1980.
6. Houston MC, Porter LL, Jenkins DE, Flexner JM. Acute Immune Hemolytic Anemia in Adults after Cytomegalovirus Infection. Southern Medical Journal 73:1270-1274, 1980.
7. Houston MC, McChesney JA, Chatterjee K. Pericardial Effusion Associated with Minoxidil Therapy. Archives of Internal Medicine 141:69-71, 1981.
8. Houston MC. Clonidine Hydrochloride: Review of Pharmacologic and Clinical Aspects. Progress in Cardiovascular Disease. 23:337-350, 1981.
9. Hines S, Houston MC, Robertson D. The Clinical Spectrum of Autonomic Dysfunction. American Journal of Medicine 70:1091-1096, 1981.
10. Houston MC. Pleural Effusion: Diagnostic Value of Measurements of PO2, PCO2 and pH. Southern Medical Journal 74:585-589, 1981.
11. Garratty G, Houston MC, Petz LD, Webb M. Acute Immune Intravascular Hemolysis Due to Hydrochlorothiazide. American Journal of Clinical Pathology 76:73-78, 1981.
12. Houston MC. Abrupt Cessation of Treatment in Hypertension: Consideration of the Clinical Features, Mechanisms, Prevention and Management of the Discontinuation Syndrome. American Heart Journal102:415-430, 1981.
13. Houston MC. Abrupt Discontinuation of Antihypertensive Therapy. Southern Medical Journal 74:1112-1123, 1981.
14. Houston MC. Clonidine Hydrochloride. Southern Medical Journal 75:713-721, 1982.
15. Houston MC. Evaluation of Risk in Abrupt Discontinuation of Antihypertensive Medications in Research Subjects. IRB A Review of Human Subjects Research 6:9-11, January/February, 1984.
16. Houston MC, Thompson WL, Robertson D. Shock: Diagnosis and Management. Archives of Internal Medicine 144:1433-1439, 1984.
17. Houston MC. Oral Clonidine Loading in Hypertensive Emergencies. Hospital Formulary 20:236, February 1985.
18. Houston MC. Examining Dietary Sodium as Cause and Therapy in Hypertension. Consultant pp. 235-245 May 1985.
19. Houston MC, Parker MM. What We Don’t Know About Septic Shock Inhibits Specific Management. Emergency Medicine Reports 6:97-104, Winter/Spring 1985.
20. Houston MC. Thiazides and Thiazide-Like Diuretics in Hypertension. Annals of Internal Medicine 103:303, August 1985.
21. Houston MC. Oral Clonidine Loading in the Treatment of Hypertensive Urgencies and Emergencies: A Review. Cardiovascular Reviews and Reports 6:1249-1252, November 1985.
22. Houston MC. Special Considerations in the Management of Septic Shock in the Elderly. Geriatric Medicine Today 5:65-77, January 1986.
23. Houston MC. Sodium and Hypertension: A Review. Archives of Internal Medicine 146:179-185, January 1986.
24. Houston MC. Hypertensive Emergencies and Urgencies: Pathophysiology and Clinical Aspects. American Heart Journal 111:205-210, January 1986.
25. Murray J, Houston MC. Multiple Calcified Intracranial Metastases from Breast Carcinoma with a Therapeutic Response to Tamoxifen. Southern Medical Journal 79:253-254, February 1986.
26. Houston MC. Adverse Effects of Antihypertensive Drug Therapy on Glucose Intolerance. Cardiology Clinics 4:117-135, February 1986.
27. Houston MC. Treatment of Hypertensive Emergencies and Urgencies with Oral Clonidine Loading and Titration: A Review. Archives of Internal Medicine 146:586-589, March 1986.
28. Houston MC, Marion JM, Curry WA. Necrotizing Arteries Associated with Blastomycosis. Southern Medical Journal 79:519-520, April 1986.
29. Houston MC. Treatment of Hypertensive Emergencies and Urgencies with Nifedipine. American Heart Journal 111:963-969, May 1986.
30. Houston MC. Hypertensive Urgencies and Emergencies: Pathophysiology, Clinical Aspects and Treatment. Critical Care: State of the Art (Society of Critical Care Medicine Yearbook 1986) Vol. 7, pp. 151-246, 1986.
31. Houston MC. Antihypertensive Therapy, Serum Lipids, Coronary Heart Disease Risk and Hypertension: Balancing the Risks and Benefits of Treatment. Western Journal of Medicine 145:219-221, August 1986.
32. Houston MC, Johnston PE. Essential Hypertension: New Insights and Controversies in Treatment with Diuretics. Southern Medical Journal 79:984-990, August 1986.
33. Houston MC. Treatment of Hypertensive Emergencies and Urgencies with Oral Clonidine Loading and Titration: A Review. In: Rogers DE, DesPrez RM, Cline MJ, et al. Eds. 1987 The Year Book of Medicine. Chicago: Year Book Medical Publishers, Inc., 1987:698-700.
34. Houston MC.. Treatment of Severe Hypertension and Hypertensive Crisis with Nifedipine. Western Journal of Medicine 146:701-704, June 1987.
35. Ferguson RK, Houston MC, Jackson RE, Liebson PR. Hypertensive Emergency. Patient Care pp. 124-139, August 15, 1987.
36. Houston MC. Pleural Fluid Ph: Diagnostic, Therapeutic, and Prognostic Value. American Journal of Surgery 154:333-337, September 1987.
37. Houston MC, Ratcliff D, Hays T, Gluck FW. Preoperative Medical Consultation and Evaluation of Surgical Risks. Southern Medical Journal 80:1385-1397, November 1987.
38. Houston MC. An Antihypertensive Role for Nifedipine. Emergency Medicine 19:176-180, December 1987.
39. Houston MC. The Comparative Effects of Clonidine, Hydrochloride and Nifedipine in the Treatment of Hypertensive Crises. American Heart Journal 115:152-159, January 1988.
40. Houston MC. The Effects of Antihypertensive Drugs on Glucose Intolerance in Hypertensive Non-Diabetics and Diabetics. American Heart Journal 115:640-656, March 1988.
41. Houston MC. Treatment of Hypertensive Urgencies and Emergencies: Comparisons of Nifedipine and Clonidine. Medical Rounds 1:148-155, April 1988.
42. Houston MC, Hodge R. Beta-Adrenergic Blocker Withdrawal Syndromes in Hypertension and Other Cardiovascular Diseases. American Heart Journal 116:515-523, August 1988.
43. Houston MC. Pre-Operative Medical Consultation and Evaluation of the Surgical Patient. MedicalRounds l (s):208-224, November 1988.
44. Houston MC. Approaches to the Treatment of Hypertension in Diabetic Patients. Cardiovascular Reviews and Reports 9 (11):30-35, November 1988.
45. Feinsilver SH, Houston MC, Sahn SA. Recognizing and Managing Pleural Effusions. Patient Care 22 (19):30-54, November 1988.
46. Houston MC. Coronary Heart Disease Risk Factors and Serum Lipids: An Evaluation of the Risks and Benefits of Various Antihypertensive Drug Therapies. Accepted for Publication: Journal American Academy Physician Assistants, December 1988.
47. Houston MC. New Insights and Approaches to the Treatment of Essential Hypertension: Selection of Therapy Based on Coronary Heart Disease Risk Factor Analysis, Hemodynamic Profiles, Quality of Life and Subsets of Hypertension. American Heart Journal 117 (4):911-951, April 1989.
48. Houston MC. Sequence of Abrupt Withdrawal of Antihypertensive Therapy. (Accepted for publication in International Proceedings Journal, June 1989.) International Medical NEWS Group.
49. Houston MC. Antihypertensive Drugs and Effects of Abrupt Cessation. Highlights June 1989.
50. Houston MC. How Dietary Sodium Can Be Effective in Treating Hypertension. Consultant 29 (7):92-97, July 1989.
51. Houston MC. Pathophysiology, Clinical Aspects, Diagnosis and Treatment of Hypertensive Crises. Progress in Cardiovascular Diseases 32 (2):99-148, September 1989.
52. Houston MC. Treatment of Hypertension in Diabetes Mellitus. American Heart Journal 118 (4):819-829, October 1989.
53. Houston MC. Abrupt Cessation of Treatment in Hypertension. Cardiovascular Review and Reports December 1989.
54. Houston MC. Selection of Antihypertensive Therapy. American Heart Journal 119 (6):1446-1447, 1990.
55. Houston MC. Pathophysiology of Shock. Critical Care Nursing Clinics of North America Vol 2, No. 2:143-149, June 1990.
56. Houston MC, Burger C, Hays JT, Nadeau J, et al. The Effects of Clonidine Hydrochloride Versus Atenolol Monotherapy on Serum Lipids, Lipid Subfractions and Apolipoproteins in Mild Hypertension. American Heart Journal 120:172-179, July 1990.
57. Houston MC. Nonsteroidal Anti-Inflammatory Drugs and Antihypertensives. American Journal of Medicine 90 (Suppl 5A):42S-47S, 1991.
58. Houston MC. Evaluating Risks and Benefits of Drug Therapies for Mild Hypertension. Journal of American Academy of Physician 4:55-62, 1991.
59. Houston MC. Interactions Between NSAIDs and Antihypertensive Drugs. The Journal of Musculoskeletal Medicine 8 (No. 8):31-46, August 1991.
60. Houston MC. Hypertension Strategies for Therapeutic Intervention and Prevention of End Organ Damage Primary Care: Clinics in Office Practice. Hypertension 8 (No. 3):713-753, September 1991.
61. Houston MC, Olafsson L, Burger MC, Lichtenstein MJ. Effects of Nifedipine GITS and Atenolol Monotherapy on Serum Lipids, Blood Pressure, Heart Rate and Weight in Mild to Moderate Hypertension. Angiology. 42 (No. 9):681-690, September 1991.
62. Houston MC. Hypertension Strategies for Therapeutic Intervention and Prevention of End-Organ Damage. Primary Care 18:713-753, 1991.
63. Houston MC. Exercise and Hypertension: Maximizing the Benefits in Patients Receiving Drug Therapy. Postgraduate Medicine 92 (6):139-153, 1992.
64. Houston, MC. New Insights and Approaches to Reduce End Organ Damage in the Treatment of Hypertension: Subsets of Hypertension Approach. American Heart Journal 123:1337-1367, 1992.
65. Houston MC. Impact of Antihypertensive Drug Therapy on Serum Lipids. Choices in Cardiology 5 (Suppl 2):10-12, 1992.
66. Feinsilver SH, Houston MC, Sahn SA. Effusions Fast Tract Management. Patient Care pp. 92-133, 1992.
67. Houston MC. Hypertension in a Marathon Runner and Hypertensive End Organ Damage. Hypertension Case and Comment. Patient Care Vol. 269 (No. l):338-339, 1992.
68. Houston MC. Hypertension with Concomitant Diseases. Hypertension Case and Comment. Patient Care Vol. 26 (No 19):105, 1992.
69. Houston MC. Coexistent Hypertension and Diabetes: Therapeutic Recommendation. PrimaryCardiology 18 (2):80-91, February 1992.
70. Houston MC. Focus on Concomitant Antihypertensive and NSAID Use. Case Studies in Hypertension Vol. 1 (l):l-4, April 1992.
71. Houston MC. Hypertension Strategies for Therapeutic Intervention and Prevention of End Organ Damage. Hospital Rounds June 1992.
72. Houston MC. Alpha Blockers: An Effective Extension to Your Patient’s Risk Reduction. Journal of Clinical Pharmacology 33:264-271, 1993.
73. Houston MC. The Management of Hypertension and Associated Risk Factors for the Prevention of Long Term Cardiac Complications. Journal of Cardiovascular Pharmacology Raven Press. 21 (Suppl):S2-S13, 1993.
74. Houston MC. Hypertension and Coronary Heart Disease Risk Factor Management. Clinical Autonomic Research 3:357-361, December 1993.
75. Houston MC, Hays L. Transdermal Clonidine as an Adjunct to Nifedipine – GITS Therapy in Patients with Mild to Moderate Hypertension. American Heart Journal 126:918-923, 1993.
76. Houston MC. Practical Guidelines to Reduce End Organ Damage in Hypertension Treatment. Today in Medicine pp. 15-17, July-August, 1993.
77. Houston, MC. The Management of Hypertension and Associated Risk factors for the Prevention of Long-Term Cardiac Complications. Journal of Cardiovascular Pharmacology 21 (Suppl. 2):S2-S13, 1993.
78. Houston MC. Hypertension and Coronary Heart Disease Risk Factor Management. Australian Family Physician Vol. 23 (No. 2):243-251 February, 1994.
79. Houston MC, Weir M, Gray J, Ginsberg D, Szeto C, Kaihienen PM, Sugimoto D and Runde M. The Effects of Nonsteroidal Anti-Inflammatory Drugs on Blood Pressure in Hypertensive Patients Controlled by a Calcium Channel Blocker. Archives of Internal Medicine 155:1049-1054, 1995.
80. Houston MC. Strategies to Reduce End Organ Damage in the Treatment of the Elderly Hypertensive Patient. Third International Congress on Hypertension in the Elderly. Accepted for publication November 1995.
81. Bakris G, Houston MC, Messerii FH. Effective Use of Combination Therapy in Hypertension. Patient Care Fall:10-21, 1997.
82. Houston MC. Hypertension and Coronary Heart Disease Risk Factor Management. Multiple Risk Factors in Cardiovascular Disease; Strategies of Prevention of Coronary Heart Disease and Cardiac Failure. Edited – Gotto AM, Lenfant C, Pavetti R, et al. Kluwer Academic Publishers, Giovanni Lorenzirn Medical Foundation, Milan, Italy, Houston, Texas, USA , pp. 335-349, 1998.
83. Houston MC. Alpha 1-Blocker Combination Therapy for Hypertension. Postgraduate Medicine 104:167-170.
84. Bakris, GL, Black, HR, Frohlich, ED, Houston, MC. New Trends in Hypertension Management. Patient Care pp. 46-80, January 30, 1999.
85. Houston MC. ALPHA1-Blocker Combination Therapy for Hypertension. Patient Care 104 (3):167-187, 1998.
86. Houston MC, Strupp JA. Prevention and Treatment of Cancer: Is the Cure in the Produce Aisle? (Editorial Commentary) JANA 3 (No. 3):1-3, 2000.
87. Colodny LR, Montgomery A, Houston MC. The Role of Esterin Processed Alfalfa Saponins in Reducing Cholesterol. JANA 3 (4):6-15, 2001 (Winter).
88. Houston MC, Montgomery A. Interview Editor-in-Chief JANA. JANA 5 (1):9-11, 2002.
89. Houston MC. The Role of Vascular Biology, Nutrition and Nutraceuticals in the Prevention and Treatment of Hypertension. JANA Suppl 1:5-71, April 2002.
90. Raymond N, Houston MC. Take the Pressure Off Your Heart: Control Hypertension. Great Life February:27-30, 2002.
91. Houston MC. Hypertension: A Complementary Approach. Natural Pharmacy 6 (5):1, 18-20, 2002.
92. Houston MC. Nutrition and Nutraceuticals in the Prevention and Treatment of Hypertension. Townsend Newsletter. Accepted 5/02.
93. Houston MC. Nutrition, Vitamins, Antioxidants and Hypertension. Total Health Magazine. Accepted 5/02.
94. Houston MC, Hungerford DS, Krueger R, Eddington ND, Foley C, Montgomery A, Fox B. Comments on joint remedies article in Consumer Reports (Editorial). JANA 5 (1):1-2, 2002.
95. Houston MC, Asher JR, Naftilan AJ, Hawkins RG. Hypertension Institute ALLHAT Clinical Trial Review: ALLHAT Not All that it’s Cracked Up to Be: Review of the Facts and the Science. Editorial Opinion. JANA 6 (1):1-4, 2003 (Winter).
96. Houston MC. Book Review. The Paleo Diet. JANA 6 (1):41-43, 2003 (Winter).
97. Houston MC. ALLHAT Debate: Diuretics are Not Preferred, First-Line Initial Therapy for Hypertension (Letter to the Editor). Archives of Internal Medicine 164:570-572, 2004.
98. Houston MC. What Your Doctor May Not Tell You About High Blood Pressure. Bottom Line Health 18:3-5, August 2004.
99. Houston MC. The Metabolic Syndrome. Saint Thomas Journal 3:13-17, 2005.
100. Houston MC. Meta-Analysis, Metaphysics and Mythology. Scientific and Clinical Perspective on the Controversies Regarding Vitamin E for the Prevention and Treatment of Disease in Humans (Editorial). JANA 8 (1):4-7, 2005.
101. Standridge JB, Sealey JE, Laragh JH, Houston MC, Gavras H, Johnson RJ, Blumenfeld JD, Brown M, Egan BM, Meltzer JI, Shimosawa T, Fujita T. A Free-Ranging Roundtable Discussion on Hypertension. Journal of Human Hypertension advance online publication, 17 February 2005; doi:10.1038/sj.jhh.1001811.
102. Houston MC, Egan BM. The Metabolic Syndrome. Pathophysiology, Diagnosis, Clinical Aspects, Prevention and Nonpharmacologic Treatment: Emphasis on Lifestyle Modifications, Nutrition, Nutritional Supplements, Vitamins, Minerals, Antioxidants, Weight Management and Exercise. JANA 8 (2):3-83, 2005.
103. Bestermann W, Houston MC, Basile J, Egan B, Ferrario CM, Lackland D, Hawkins RG, Reed J, Rogers P, Wise D, Moore MA. Addressing the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome in the Southeastern United States, Part II: Treatment Recommendations for Management of the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome. The American Journal of the Medical Sciences 329:292-305, 2005.
104. Houston MC, Basile J, Bestermann WH, Egan B, Lackland D, Hawkins RG, Moore MA, Reed J, Rogers P, Wise D, Ferrario CM. Addressing the Global Cardiovascular Risk of Hypertension, Dyslipidemia, and Insulin Resistance in the Southeastern United States. The American Journal of the Medical Sciences 329:276-291, 2005.
105. Hawkins RG, Houston MC. Is Population-Wide Diuretic Use Directly Associated with the Incidence of End-Stage Renal Disease in the United States? A Hypothesis. American Journal of Hypertension 18:744-749, 2005.
106. Houston MC. Nutraceuticals, Vitamins, Antioxidants and Minerals in the Prevention and Treatment of Hypertension. Progress in Cardiovascular Diseases 47:396-449, 2005.
107. Standridge JB, Sealey JE, Laragh JH, Houston MC, Gavras H, Johnson RJ, Blumenfeld JD, Brown M, Egan BM, Meltzer JI, Shimosawa T, Fujita T. A Free-Ranging Roundtable Discussion on Hypertension. Journal of Human Hypertension 19:259-266, 2005.
108. Houston MC, Mann SJ. Treating Hypertension in Patients with Concomitant Disorders. Patient Care 40:47-52, 2006.
109. Ravnskov U, Rosch PJ, Sutter MC, Houston MC. Controversy. Should We Lower Cholesterol As Much As Possible? British Medical Journal 332:1330-1332, 2006.
110. Messerli FH, Bakris GL, Ferrera D, Houston MC, Petrella RJ, Flack JM, Sun W, Lee E, Neutel JM; AVALON Investigators. Efficacy and Safety of Coadministered Amlodipine and Atorvastatin in Patients with Hypertension and Dyslipidemia: Results of the AVALON Trial. Journal of Clinical Hypertension 8:571-581, 2006.
111. Basile JN, Houston M, Ferrario C. Incremental Risk-Factor Reduction Improves Overall Cardiovascular Benefit: Is It Time To Abandon The Silos? The Journal of Clinical Hypertension 8:688-696, 2006.
112. Houston M. Are You Getting Too Much Salt? Bottom Line Health 20:1-3, 2006.
113. Basile J, Houston M, Ferrario CM. Treating the Cardiometabolic Syndrome: An Opportunity to Provide Comprehensive Cardiovascular Risk Reduction. Journal of the CardioMetabolic Syndrome 1:358-361, 2006.
114. Houston MC. The Role of Mercury and Cadmium Heavy Metals in Vascular Disease, Hypertension, Coronary Heart Disease, and Myocardial Infarction. Alternative Therapies in Health and Medicine 13:S128-S133, March/April 2007.
115. Houston MC. Treatment of Hypertension with Nutraceuticals, Vitamins, Antioxidants and Minerals. Expert Review of Cardiovascular Therapy 5:681-691, 2007.
116. Asher J, Houston M. Statins and C-Reactive Protein Levels. The Journal of Clinical Hypertension 9:622-628, 2007.
117. Ferrario CM, Basile, J, Bestermann W, Frohlich E, Houston M, Lackland DT, Smith RD, Wise, DL. The Role of Noninvasive Hemodynamic Monitoring in the Evaluation and Treatment of Hypertension. Therapeutic Advances in Cardiovascular Disease 1:113-118, 2007.
118. Houston MC, Cooil B, Olafsson BJ, Raggi P. Juice Powder Concentrate and Systemic Blood Pressure, Progression of Coronary Artery Calcium and Antioxidant Status in Hypertensive Subjects: A Pilot Study. Evidence-Based Complementary and Alternative Medicine 4:455-462, 2007.
119. Houston M, Sparks W. Latest Finding on Essential Fatty Acids and Cardiovascular Health. Accepted for publication in The Original Internist June 2008.
120. Houston MC, Harper KJ. Potassium, Magnesium, and Calcium: Their Role in Both the Cause and Treatment of Hypertension. The Journal of Clinical Hypertension 10:3-11, 2008.
121. Moser M, Houston M, Svetkey L, Egan B. Dietary Management in the Prevention and Treatment of Hypertension: Does it Work? The Journal of Clinical Hypertension 10:632-639, 2008.
122. Houston M. What Most Doctor’s Won’t Tell You About High Blood Pressure. Bottom Line Health 22:8-9, December 2008.
123. Houston MC. Treatment of Hypertension with Nutraceuticals, Vitamins, Antioxidants and Minerals. Florida Family Physician 57:20-27, Winter 2008.
124. Houston M. Chocolate and Hypertension. Bottom Line Health 23:16, February 2009.
125. Cohn JN, Wilson DJ, Neutel J, Houston M, Weinberger MH, Grimm R Jr., Smith DH, Sun W. Coadministered Amlodipine and Atorvastatin Produces Early Improvements in Arterial Wall Compliance in Hypertensive Patients with Dyslipidemia. American Journal of Hypertension 22(2):137-144, 2009.
126. Houston, MC, Fazio,S, Chilton, FH, Wise, DE, Jones, KB, Barringer, TA and Bramlet,DA. Nonpharmacologic Treatment of Dyslipidemia. Progress in Cardiovascular Disease 2009; 52: 61-94.
127. Houston , MC and Sparks, W. Effect of Combination Pantethine, Plant Sterols, Green Tea Extract, Delta-tocotrienol and Phytolens on Lipid Profiles in Patients with Hyperlipidemia. JANA 2010: 13(1): 15-20.
128. Houston, MC. The Role of Cellular Micronutrient Analysis, Nutraceuticals, Vitamins, Antioxidants and Minerals in the Prevention and Treatment of Hypertension and Cardiovascular Disease. Therapeutic Advances in Cardiovascular Disease. 2010.4(3):165-83.
129. Houston Mark C. Nutrition and Nutraceutical Supplements in the Treatment of Hypertension. Expert Review in Cardiovascular Therapy; 2010;8(6) June: 821-833.
130. Giles TD and Houston MC. Do Diuretics Diminish the Predicted Benefits on Ischemic Heart Disease Event of Lowering Blood Pressure in Hypertension? The Journal of Clinical Hypertension 2010;12(7): 469-471.
131. Houston MC. Resetting Your Biological Clock: How to Slow the Aging Process and Live Longer Townsend Letter. 2010; 329 (December): 52-54.
132. Houston MC. The Importance of Potassium in Managing Hypertension. Curr Hypertens Rep. 2011;13(4): 309-317.
133. Houston Mark C. Role of Mercury Toxicity in Hypertension, Cardiovascular Disease and Stroke. J. Clin Hypertension 2011; 13: 621-627.
134. Houston MC. The Role of Magnesium in Hypertension and Cardiovascular Disease. J of Clinical Hypertension. 2011; 13 (11): 843-7.
135. Houston MC. The Role of Nutraceutical Supplements in the Treatment of Dyslipidemia. J of Clinical Hypertension. 2012; 14: 121-132.
136. Papas AM and Houston MC. The Synergistic Potential of Natural Anti-inflammatory and Antioxidant Compounds in the Prevention, Management and Treatment of Cardiovascular Disease and Hypertension. Anti-Aging Medical News. Fall 2012. pp 10-14.
137. Houston Mark C. The role of Nutrition and Nutraceutical Supplements in the Prevention and Treatment of Hypertension. Clin Pract 2013:10(2): 209-229.
138. Houston Mark C. Endothelial Dysfunction and the Preventative Approach to Cardiovascular Disease; IMCJ 2013;12(2): 53-57.
139. Houston Mark C. Combination Nutraceutical Supplement Lowers Blood Pressure in Hypertensive Individuals. Integrative Medicine 2013;12(3): 22-28
140. Houston MC. The Role of Nutrition, Nutraceuticals, Vitamins, Antioxidants and Minerals in the Prevention and Treatment of Hypertension. Altern Ther Health Med. 2013;19 (suppl 1): 32-49
141. Houston Mark C. New Concepts in Cardiovascular Disease. J of Restorative Medicine 2013;2:30-44.
142. Houston Mark. Nutrition and Nutraceutical Supplements for the Treatment of Hypertension: Part 1. J. Clinical Hypertension 2013;15:752-757.
143. Houston Mark C. On the Precipice of a Revolution in the Treatment of Cardiovascular Disease. Anti-Aging Therapeutics . 2013. XV:49-58.
144. Houston Mark. Nutrition and Nutraceutical Supplements for the Treatment of Hypertension: Part II. J. Clinical Hypertension 2013;15:845-851.
145. Houston Mark. Nutrition and Nutraceutical Supplements for the Treatment of Hypertension: Part III J Clinical Hypertension 2013;15:931-7.
146. Sinatra ST, Teter BB, Bowden J, Houston MC, Martinez-Gonzalez MA. The saturated fat, cholesterol, and statin controversy a commentary. J Am Coll Nutr. 2014 Feb;33(1): 79-88.
147. Houston Mark C. The Role of Mercury in Cardiovascular Disease. J of Cardiovascular Diseases and Diagnosis. 2014;170
148. Houston Mark. The Role of Nutrition and Nutraceutical supplements in the Treatment of Hypertension. World Journal of Cardiology 2014;6(2): 38-66
149. Sinatra ST, Teter BB, Bowden J,Houston MC, Martinez-Gonzalez MA. The cholesterol and statin controversy: the new 2013 statin-cholesterol guidelines. Altern Ther Health Med. 2014 Sep-Oct;20(5):14-7.
150. Houston Mark C. New Concepts in the Diagnosis and Non- Surgical Treatment of Cardiovascular Disease; Internal Medicine: Open Access 2014  ISSN 2165-8048 IME. S12-S20.
151. Houston Mark. Avoiding the Cardiovascular Precipice: New Developments in Evaluation and Lifestyle Medicine. Townsend Newsletter 2014; May 46-51
152. Houston Mark C. Managing Cardiovascular Disease Form an Innovative Perspective for Improved Outcomes. The Journal of Restorative Medicine. On line May 28,2014. http://restorativemedicine.org/journal.
153. Houston M. and Hays L Acute Effects of an Oral Nitric Oxide Supplement on Blood Pressure, Endothelial Function, and Vascular Compliance in Hypertensive Patients. J of Clinical Hypertension 2014: 1-6.
154. Houston M, Guarneri M, Kahn J. ISIFMC Position Paper on the HPS2-THRIVE Study. International Journal of Human Nutrition and Functional Medicine 2014; 2(3): 1-5.
155. Houston, Mark. The role of nutrition and nutritional supplements in the treatment of dyslipidemia. Clinical Lipidology 2014;9(3): 333-354.
156. Houston, M and Pizzorno J. “Niacin Doesn’t Work and Is Harmful/” Proclaim the Headlines. Yet Another Highly Publicized Questionable Study to Discredit Integrative Medicine. Integrative Medicine 2014;13 (5):8-11.
157. Houston M and Minich DM. Fructose-containing sugars do not rise blood pressure or uric acid at normal levels of human consumption: J Clin Hypertens 2015; 17:95-97.
158. Houston, Mark. Applying Nutragenomics to Cardiovascular Medicine: Prevention and Treatment. Townsend Letter. December 2015: 48-53.
159. Houston M. et al. A Placebo-Controlled Trial of a Proprietary Lipid-Lowering Nutraceutical Supplement in the Management of Dyslipidemia. J of Biological Regulators and Homeostatic Agents. 2016; 30:1115-1123.
160. Houston MC. Saturated Fats and Coronary Heart Disease. Annals of Nutritional Disorders and Therapy. 2017;4(1):1038-40.
161. Houston MC. The Role of Saturated Fats in Coronary Heart Disease. J of Heart and Stroke. 2017;2(3): 1025-26.
162. Houston Mark. The Relationship of Saturated Fats and Coronary Heart Disease: Fa( c) t or Fiction: A Commentary. Ther Adv Cardiovascular Disease 2017; 1:5
163. Houston M, Minich D, Sinatra ST, Kahn JK, Guarneri M.Recent Science and Clinical Application of Nutrition to Coronary Heart Disease. J Am Coll Nutr. 2018 Jan 9:1-19.
164. Houston M. The role of noninvasive cardiovascular testing, applied clinical nutrition and nutritional supplements in the prevention and treatment of coronary heart disease. Ther Adv Cardiovasc Dis. 2018 Mar;12(3):85-108. Epub 2018 Jan 10
165. Houston, Mark. Cardiovascular Disease: Good Fats and Bad Fats. EC Cardiology 2018;5.5:239-246.
166. Houston, Mark and Rountree, Robert. The Application of Nutrition for Cardiovascular Disease. Alternative and Complementary Medicine 2018;24(4),1-7.
167. Houston Mark et al. Clinical Roundup: Selected Treatment Options for Hyperlipidemia. Alternative and Complementary Medicine 2018;24(5):1-4
168. Houston Mark. Treatment of Hypertension with Nutrition and Nutraceutical Supplement: Part 1. Alternative and Complimentary Medicine. 2019 ;24: 260-275
169. Houston Mark. Treatment of Hypertension with Nutrition and Nutraceutical Supplement: Part 2. Alternative and Complimentary Medicine. 2019 ;25: 23-36
170. Houston Mark. Nutrition and Nutraceutical Supplements in the Management of Dyslipidemia-Part 1. Alternative and Complementary Medicine 2019;25(2):77-84
171. Houston Mark. Nutrition and Nutraceutical Supplements in the Management of Dyslipidemia-Part 2. Alternative and Complementary Medicine 2019;25(1):23-36
172. Houston Mark. Three Finite Vascular Responses that Cause Coronary Heart Disease and Cardiovascular Disease: Implications for Diagnosis and Treatment. Alternative and Complimentary Medicine. 2019;25(4):181.

1. Acute Hemolytic Anemia Associated with Antibodies to Hydrochlorothiazide. Presented at the 29th Annual Meeting of the American Associated of Blood Banks. San Francisco, California. November 6, 1976.
2. Houston MC. Clonidine Hydrochloride: Review of Pharmacological and Clinical Aspects. International Synopses, Cardiology Digest, page 15, February 1982.
3. Houston MC, Hays T, Nadeau J. Olafsson L, Burger C. Effects of Clonidine and Atenolol Monotherapy on Serum Lipids, Lipoproteins and Glucose in Mild Hypertension. Presented at the American Federation of Clinical Research. New Orleans, Louisiana. January 29, 1987.
4. Houston MC, Hays T, Nadeau J, Olafsson L. Burger C. Effects of Clonidine and Atenolol Monotherapy in Serum Lipids, Lipoproteins and Glucose in Mild Primary Hypertension. Clinical Research 35:348A,1987.
5. Houston MC. Effects of Antihypertensive Drug Therapy on Glucose Tolerance. First International Symposium on Heart Failure: Mechanisms and Management. Jerusalem, Israel. May 1989.
6. Houston MC, Hodge R. Beta-Adrenergic Blocker Withdrawal Syndromes in Hypertension and Other Cardiovascular Diseases. American Heart Journal 116 (2-Part l):515-523, August 1988.
7. Houston MC. New Insights and New Approaches for Treatment of Essential Hypertension: Selection of Therapy Based on Coronary Heart Disease Risk Factor Analysis. Hemodynamic Profiles, Quality of Life and Subsets of Hypertension. Cardiology Digest 7:23-34, 1989.
8. Houston MC. New Insights and New Approaches for the Treatment of Essential Hypertension: Selection of Therapy Based on Coronary Heart Disease Risk Factor Analysis, Hemodynamic Profiles, Quality of Life and Subsets of Hypertension. Abstracts International. March 1990.
9. Houston MC, Burger MC, Olafsson L. Effects of Clonidine Hydrochloride and Atenolol Monotherapy Serum Lipids in Mild Hypertension. Published American Society of Hypertension, May 1990. American Journal of Hypertension 3 (5):3A, 1990.
10. Houston MC, Olafsson L, Burger MC, Lichtenstein MJ. Effects of Nifedipine GITS and Atenolol Monotherapy on Blood Pressure, Heart Rate and Weight in Mild to Moderate Hypertension. Published American Society of Hypertension, May 1990. American Journal of Hypertension 3 (5):4A, 1990.
11. Houston MC, Olafsson L, Burger MC, Lichtenstein JM. Effects of Nifedipine GITS and Atenolol Monotherapy on Serum Lipids in Mild to Moderate Hypertension. American Society of Hypertension, May 1990. American Journal of Hypertension 3 (5):4A, 1990.
12. Houston MC, Olafsson L, Burger MC, Lichtenstein MJ. Effects of Nifedipine GITs and Atenolol Monotherapy on Blood Pressure, Heart Rate and Weight in Mild to Moderate Hypertension. American Fed Clinical Research, 1990.
13. Houston MC, Olafsson L, Burger MC, Lichtenstein MJ. Effects of Nifedipine GITS and Atenolol Monotherapy on Serum Lipids in Mild to Moderate Hypertension. American Fed Clinical Research, 1990.
14. Houston MC, Olafsson L, Burger MC, Lichtenstein MJ. Effects of Nifedipine GITS and Atenolol Monotherapy on Blood Pressure, Heart Rate and Weight in Mild to Moderate Hypertension. Presented International College of Angiology. Toronto, Canada, June 1990.
15. Houston MC, Olafsson L. Burger MC, Lichtenstein MJ. Effects of Nifedipine GITS and Atenolol Monotherapy on Serum Lipids in Mild to Moderate Hypertension. Presented International College of Angiology, Toronto, Canada, June 1990.
16. Houston MC, Olafsson L. Effects of Nifedipine GITS on Lp(c). American Society of Hypertension. New York, New York, May 1991. American Journal of Hypertension 4 (No. 5):24A, 1991.
17. Houston MC, Olafsson L. Nifedipine GITS and Lipids. National Cholesterol Council Poster. April 7-10, 1991.
18. Houston MC, Olafsson L. Effects of Nifedipine GITS and Atenolol Monotherapy on Lipoprotein a (Lpa) in Hypertension. Southern Medical Association 85th Annual Assembly. Atlanta, Georgia. November 16-19, 1991.
19. Houston MC, Olafsson L. Effects of Clonidine Hydrochloride and Atenolol Monotherapy on Quality of Life in Mild Hypertensive Patients. 57th Annual Scientific Assembly American College of Chest Physicians. San Francisco, California. November 5, 1991. Chest 100 (2):715, August 1991.
20. Houston MC, Olafsson L. Effects of Nifedipine GITS and Atenolol Monotherapy on Lipoprotein a (Lpa) in Hypertension. 57th Annual Scientific Assembly American College of Chest Physicians. San Francisco, California. November 16-19, 1991.
21. Houston MC, Hays L. Nifedipine GITS vs. Atenolol on Serum Lipids, Quality of Life and Efficacy in Hypertension. Inter-American Society of Hypertension (IASH), April 1993.
22. Houston MC, Hays L. Nifedipine GITS plus Clonidine TTS in the Treatment of Hypertension. Inter-American Society of Hypertension (IASH), April 1993.
23. Houston MC, Hays L. Comparative Effect of Nifedipine GITS and Atenolol Monotherapy on Lipids and Lipoprotein Subfractions in Hypertension. American Society of Hypertension. American Journal of Hypertension 15 (4) Part 2 (P-12):37A, 2002.
24. Hawkins RG, Houston MC. Correlations Among Trends in Cardiovascular Mortality, Hypertensive Nephrosclerosis and Antihypertensive Medication Prescriptions in North America. American Society of Hypertension, American Journal of Hypertension 15 (4) Part 2 (P-310):142A, 2002.
25. Hawkins RG, Houston MC. Renal Failure Incidence Rates within Countries are Associated with Hypertension Treatment, Not Hypertension Prevalence. 10th Annual COSEHC National Scientific Sessions, October 2003.
26. Hawkins RG, Houston MC. Analysis of Antihypertensive Drug Use and ESRD Incidence in Canada and the United States. 10th Annual COSEHC National Scientific Sessions, October 2003.
27. Hawkins RG, Houston MC. American Spending on Diuretics Directly Predicts End-Stage Renal Failure Incidence Changes in a Time-Lagged Fashion. 10th Annual COSEHC National Scientific Sessions, October 2003.
28. Hawkins RG, Houston MC. Analysis of Antihypertensive Drug Use and ESRD Incidence in Canada and US. American Society of Hypertension, American Journal of Hypertension 17 (5) Part 2 (OR-52):22A, 2004.
29. Hawkins RG, Houston MC. US Spending on Diuretics Directly Predicts ESRD Incidence Changes in a Time-Lagged Fashion. American Society of Hypertension, American Journal of Hypertension 17 (5) Part 2 (P-321):152A, 2004.
30. Hawkins RG, Houston MC. Renal Failure Incidence Rates within Countries are Associated with Hypertension Treatment, Not Hypertension Prevalence. American Society of Hypertension, American Journal of Hypertension 17 (5) Part 2 (P-448):197A, 2004.
31. Houston MC, Olafsson BJ, Raggi P. Efficacy of a Phytonutrient Nutritional Concentrate Powder on Systolic and Diastolic Blood Pressure and Arterial Compliance. American Society of Hypertension. San Francisco, California. May 15, 2005. American Journal of Hypertension 18 (5) Part 2 (P-113):48A, 2005.
32. Houston MC, Olafsson BJ, Raggi P. Efficacy of a Phytonutrient Nutritional Concentrate Powder on Coronary Artery Calcification and Calcium Score (CS) Assessed by Electron Beam Tomography (EBT). American Society of Hypertension. San Francisco, California. May 15, 2005. American Journal of Hypertension 18 (5) Part 2 (P-112):48A, 2005.
33. Ferrario CM, Houston MC, Ferrario M, Bestermann W, Moore MA. A Consortium for Southeastern Hypertension Control (COSEHC) Regional Specific Approach for Assessing Global Cardiovascular Risk in the Southeastern USA. American Society of Hypertension. San Francisco, California. May 15, 2005. American Journal of Hypertension 18 (5) Part 2 (P-278):106A, 2005.
34. Hawkins RG, Houston MC, Ferrario CM, Moore MA, Bestermann WH. A Second Generation Approach to Cardiovascular Risk Assessment: The COSEHC Cardiovascular Risk Assessment Tool. American Society of Hypertension. San Francisco, California. May 15, 2005. American Journal of Hypertension 18 (5) Part 2 (P-382):144A, 2005.
35. Cohn JN, Neutel J, Houston M, Weinberger MH, Grimm R, Smith DHG, Rosenberg N, Wilson DJ, Sun W. Early Improvements in Vascular Compliance Following Coadministration of Amlodipine and Atorvastatin in Patients with Concomitant Hypertension and Dyslipidemia: The Avalon Arterial Wall Compliance (AWC) Trial. American Society of Hypertension. San Francisco, California. May 15, 2005.
36. Fujimura Y, Houston M, Fazio S, Sillesen H, Callahan III AS. Early Vascular Medicine Clinics: Methods, Models, and Initial Results. Global Investigators Meeting. Boston, Massachusetts. October 4-6, 2006.

1. Vascular Biology in Clinical Medicine 2002. Houston MC. Hanley and Belfus. Philadelphia, Pennsylvania.
2. Facts and Formulas Handbook 1984. Reviewer and Contributor, Written and Compiled by Dr. Robert C. Rollings. VUMC Press. Published February 1984.
3. Change of Seasons; A Comprehensive Guide to Low Salt (Sodium Living). Vanderbilt Department of Nutrition. Reviewer and Editor. July 1985 and July 1986.
4. Treatment of Hypertensive Urgencies and Emergencies. Houston MC, Anderson R, Reed G. Published by B.I.L., Connecticut. Published December 1985.
5. Handbook of Antihypertensive Therapy. Houston MC, Moore LC, Pulliam CB. Published (First Edition March 1986), (Second Edition March 1987), (Third Edition March 1988), (Fourth Edition September 1990), (Fifth Edition 1994), (Sixth Edition 1996), (Seventh Edition 1987), (Eighth Edition 1998), (Ninth Edition 1999), (Tenth Edition 2000) and (Eleventh Edition 2003).
6. Treatment of Essential Hypertension: A Comprehensive Clinical Review of Nonpharmacologic and Pharmacologic Therapy. Houston MC. (in press).
7. The Future of Centrally Acting Agents and Other Therapies for Long Term Treatment of Hypertension. Houston MC. Logical Communications, Norwalk, CT and Boehringer Ingelheim, Inc. Ridgefield, Connecticut. November 1988.
8. New Concepts in Antihypertensive Therapy. Houston MC. B.I.L., Canada. July 1989.
9. Nifedipine GITS; Relieving the Pressure. Houston MC. Produced by Cine-Med, Inc. Woodbury, Connecticut. 1991.
10. From Framingham Forward: Hypertension: Consequences and Treatment Options. Adis International Limited. Chester, England. 1992.
11. Strategies to Reduce End Organ Damage; The Subsets of Hypertension. Edwin Communications. Ontario, Canada. July 1993.
12. Houston MC: Approaches to the Treatment of Hypertension; Subsets of Hypertension. Medical Management Illustrated. Vol. 2(2), February 1993.
13. Houston MC, Fox B, Taylor N. What Your Doctor May Not Tell You About Hypertension. The Revolutionary Nutrition and Lifestyle Program to Help Fight High Blood Pressure. AOL Time Warner, Warner Books. New York, New York. September 2003.
14. Houston MC, Hawkins, R. Hypertension Handbook for Students and Clinicians: Pathophysiology, Diagnosis, Clinical Trials, Non Drug and Drug Treatments. First Edition. ANA Publishing, Birmingham, Alabama. 2005.
15. Houston, Mark C. Handbook of Hypertension. Wiley-Blackwell , Oxford UK. 2009.
16. Houston, Mark C. What Your Doctor May Not Tell You About Heart Disease. Grand Central Press, NY, NY. February 2012.
17. Nutrition and Integrative Strategies in Cardiovascular Medicine. Houston and Sinatra, Editors. CRC Press 2015.
18. Vascular Biology for the Clinician, Houston,  Mark C., Lamb, Joseph, Hays, Anita, Outskirts Press 2019.
19. Personalized and Precision Integrative Cardiovascular Medicine, Houston,  Mark C., LWW 2019

1. A Comprehensive Approach to Treating High Blood Pressure. Houston MC and Crayhon R. Designs for Health Institute, 2002.
2. Functional Medicine Update. Clinician of the Month. Vascular Biology, Hypertension, Nutrition and Nutraceuticals. Houston MC and Bland JS. Vol. 22, No. 12: December 2002.
3. VasculoSirt. An Interview with Mark Houston, MD, SCH, FACP, FAHA. Biotics Research Corporation. August 2008.
4. EFA, Sirtuins and Healthy Aging. The Latest Research in an Interview with Dr. Mark Houston. Biotics Research Corporation. January 2009.
5. Lipid-Sirt and Dyslipidemia. Biotics Research Corporation. April 2009.

1. Houston MC, Dzau V. Hypertension As Risk Factor. Chapter 23 in Textbook of Vascular Medicine. Editors: Loscaizo J, Creagler M, Dzau V. (November 1992). Little, Brown and Company Publishers.
2. Dzau V, Naftilan A, Houston MC. Hypertension Evaluation and Management. Chapter 22 in Textbook of Vascular Medicine. Editors: Loscaizo J, Creagler M, Dzau V. (November 1992). Little, Brown and Company Publishers.
3. Houston MC. Hypertension Conn’s Current Therapy. 1995 Edition. Accepted for publication. October 1994.
4. Houston, MC. Hypertension. Section 3 in Advances in Medicine. Editor: Edlich RF. (2000). ABI Professional Publications.
5. Houston MC. Centrally Acting Antihypertensive Drugs. Chapter 31, Pages 339-348 in Hypertension Medicine. Edited by: Weber MA. (2001). Humana Press, Inc.
6. Houston MC. Centrally Acting Antihypertensive Drugs. Hypertension Textbook. Edited by: Weber M. Accepted for publication, July 1999.
7. Houston MC. Hypertension. Advances in Medicine Textbook and Internet Web Site Publications. Edited by: Edlich RF. Accepted for publication, August 1999 (Publish Date: February 2000).
8. Houston MC. Nutrition, Dietary Supplements and Nutraceuticals in Hypertension. Chapter 17, Pages 181-190 in Hypertension: Hot Topics. Edited by: Egan BM, Basile JN, Lackland DT. Hanley & Belfus, Inc., 2004.
9. Houston Mark. Case Presentation and Extended Discussion : Metabolic Syndrome, Cardiovascular Disease and Related Conditions. Textbook of Functional Medicine. Chapter 37 :729-749. Institute for Functional Medicine 2005.
10. Houston MC. Treatment of Hypertension with Nutraceuticals, Vitamins, Antioxidants, and Minerals. Chapter 84, Pages 719-725 in Advanced Therapy in Hypertension and Vascular Disease. Edited by Mohler III ER, Townsend RR. BC Decker Inc., 2006.
11. Houston MC. Hypertension: Utilizing Nutrition in Treatment. Chapter 5, Pages 75-108 in Food and Nutrients in Disease Management. Edited by Kohlstadt I. CRC Press, 2009.
12. Houston MC and Sinatra ST. Cardiovascular Disease: Diagnosis, Prevention and Therapeutic Interventions. Physician’s Guide to Anti-Aging and Regenerative Medicine. First Edition 2010-2012. A4M Publications, Chicago, Ill.
13. Sinatra ST and Houston MC. The Integrative Approach to Hypertension. Integrative Cardiology by Devries, S and Dalen J in Weil Integrative Medicine Library. Oxford University Press. 224-246,2011.
14. Houston Mark. Case Presentations, Metabolic Syndrome, Cardiovascular Disease and Related Conditions: Extended Discussion. Textbook of Functional Medicine. Chapter 37: 729-749. Institute for Functional Medicine 2010.
15. Houston , Mark C. The Role of Potassium in Stroke, Cardiovascular Disease and Hypertension. Metal Ion In Stroke. Ed Yang V. Li and John H Zhang . Springer .New York, Heidelberg, Dordrecht London. 2012.
16. Houston , Mark C. The Role of Mercury and Cadmium in Cardiovascular Disease , Hypertension and Stroke: Metal Ion In Stroke. Ed Yang V. Li and John H Zhang . Springer .New York, Heidelberg, Dordrecht London. 2012.
17. Houston, Mark. Tocotrienols in the Treatment of Dyslipidemia. In Tocotrienols: Vitamin E Beyond Tocopherols. Ed Barry Tan, Ronald Watson and Victor Preedy. CRC Press, Taylor and Francis 2013.
18. Houston Mark. Magnesium and Hypertension. In Magnesium in Human Health and Disease. Ed Watson RR, Preedy VR and Zibadi S. Humana Press 2013. Pp 183-89.
19. Houston , Mark and DeBusk R. Dyslipidemia. In Advancing Medicine with Food and Nutrients. 2nd edition. Edited by Ingrid Kohlstadt . CRC Press, Taylor and Francis, Boca Raton, Fla. 2013. pp 57-81.
20. Houston ,Mark. Hypertension. In Advancing Medicine with Food and Nutrients. 2nd edition. Edited by Ingrid Kohlstadt . CRC Press, Taylor and Francis, Boca Raton, Fla. 2013. pp 105-134.
21. Houston, Mark. Hypertension: Prevention and Treatment with Nutraceucticals Vitamins, Minerals and Antioxidants. pp 69-98 Guide to Anti-Aging and Regenerative Medicine 2013-2018 Edition A4M Chicago.
22. Houston, Mark. Dyslipidemia: Non Pharmoacologic Treatment. pp 99-150 Guide to Anti-Aging and Regenerative Medicine 2013-2018 Edition. A4M Chicago.
23. Houston, Mark. Hypertension: Prevention and Treatment with Nutraceucticals Vitamins, Minerals and Antioxidants pp 99-128. Encyclopedia of Clinical Anti-aging Medicine and Regenerative Biomedical Technologies. A4M Chicago 2013
24. Houston, Mark. Dyslipidemia: Non Pharmoacologic Treatment pp 129-180 Encyclopedia of Clinical Anti-aging Medicine and Regenerative Biomedical Technologies. A4M Chicago 2013
25. Houston, Mark. Exercise and Health. The American Board of Integrative Holistic Medicine Curriculum Study Guide. Ed Sheila Quinn and Nancy Sudak MD. July 2013.
26. Houston Mark The Role of Nutraceutical Supplements in the Prevention and Treatment of Hypertension. In Nutraceuticals and Health: Review of Human Evidence. Edited by Somdat Mahabir andYashwant V. Pathak. CRC Press and Taylor and Francis. Boca Raton, Fla. 2014.
27. Houston MC. Dyslipidemia: Myths and Truths. Anti-Aging Therapeutics 2014; Volume XVI :91-105.
28. Houston MC. New and Revolutionary Concepts in the Pathophysiolog, Diagnosis and Treatment of Hypertension. Anti-Aging Therapeutics 2014; Volume XVI :107-105.
29. Houston MC. Cardiovascular Disease in “Good and Well.” 25 Experts Share their Secrets to Wellbeing. By Gillian Fish. Australia,  2016
30. Houston Mark: Hypertension and Dyslipidemia Chapters in Nutrition and Integrative Strategies in Cardiovascular Medicine. Houston and Sinatra, Editors. CRC Press 2015.
31. Steven Sinatra and Mark Houston, Editors Nutrition and Integrative Strategies in Cardiovascular Medicine. CRC Press 2015.
32. Houston, Mark, Lamb, Joe and Hays, Anita. Vascular Biology in Clinical Practice. Outskirts Press. November 2019
33. Mark C Houston, Editor. Personalized and Precision Integrative Cardiovascular Medicine. Wolters Kluwer Publishers, December, 2019.
34. Mark Houtson. Revolutionary Concepts in the Prevention and Treatment of Cardiovascular Disease, in Integrative and Functional Medical Nutrition Therapy. Humana Press Noland and Drisko Editors. pp 823-841.

1. Treatment of Hypertensive Urgencies and Emergencies with Oral Clonidine Loading. Houston MC, Anderson RA. In cooperation with Boehringer Ingelheim Ltd. Vanderbilt University Medical Center and Parkland Memorial Hospital. Nashville, Tennessee and Dallas, Texas. Wexler Productions. California.
2. Cooperative Care Center of Vanderbilt University Hospital. Vanderbilt University Productions. Ja
3. New Treatment Strategies for the Treatment of Hypertension. Medical Publishing Communications. New York, New York.
4. Treatment of Diabetes Mellitus and Hypertension. Searle. January 1990.
5. New Insights in the Treatment of Hypertension. B.I.L. Canada. March 1990.
6. Nifedipine GITS: Management of Hypertension Through Monotherapy. Medicine International PLC, London and New York. August 1990.
7. Hypertension, Exercise and Cardiovascular Disease Interrelationships. Medifacts. Ottawa, Ontario, Canada. Audiotape. 1992.
8. Expanded Lipid Profile. Diagnosis and Treatment. 2001.

1. Alternate Hypertension Drug Urged. Tennessean. Nashville, Tennessee. October 29, 1989.
2. Blood Pressure Drug May Aid Alcohol Fight. Tennessean. Nashville, Tennessee. March 5, 1989.
3. Antihypertensive Drug Delivery System To Be Studied at VUMC. Medcom. July 1, 1988.
4. Patching Up Your Health. Prevention. January 1988 (76-77).
5. Study Tests Blood Pressure Drug For Diabetes. Medcom. October 16, 1987.
6. Patch Treats High Blood Pressure. Nashville Banner. April 25, 1987.
7. When It Comes To Drugs, Cheaper Is Not Better. Washington Post. July 7, 1986.
8. Beware Of Baldness Cure. Medcom. April 16, 1986.
9. Insist On Brand Name Drugs. Tennessean. December 12, 1986.
10. Skin Patch Helps Patients With Blood Pressure Medications. Nashville Banner. December 6, 1985.
11. Some Hypertension Drugs Pose Severe Risks. National Medical Association News.
12. Internal Medicine News: International Medical News Group. ACE Inhibitors. 1995.
13. A Living, Breathing Time Bomb. Tennessean. February 2, 1999.

700 Club Febuary 8, 2012

POSTGRADUATE EDUCATIONAL LECTURES, COURSES AND SYMPOSIA AND INVITED VISITING LECTURESHIPS: PARTIAL LISTING: LIST AVAILABLE ON REQUEST. OVER 10,000 LOCAL, REGIONAL, NATIONAL, AND INTERNATIONAL VISITING LECTURES AND SYMPOSIA HAVE BEEN PRESENTED TO DATE.